| 2.46 0.03 (1.23%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.91  |
1-year : | 3.4 |
| Resists | First : | 2.49 |
Second : | 2.91 |
| Pivot price | 2.18 |
|||
| Supports | First : | 2.09 |
Second : | 1.85 |
| MAs | MA(5) : | 2.34 |
MA(20) : | 2.13 |
| MA(100) : | 1.98 |
MA(250) : | 2.68  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 88.6 |
D(3) : | 80 |
| RSI | RSI(14): 65.2 |
|||
| 52-week | High : | 4.75 | Low : | 1.26 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BTMD ] has closed below upper band by 9.1%. Bollinger Bands are 27.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.5 - 2.51 | 2.51 - 2.52 |
| Low: | 2.35 - 2.36 | 2.36 - 2.37 |
| Close: | 2.44 - 2.46 | 2.46 - 2.48 |
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
Wed, 10 Jun 2026
biote Corp. (BTMD) director receives 130,000 stock options at $2.34 strike - Stock Titan
Wed, 10 Jun 2026
biote Corp. (BTMD) Executive Chairman receives 114,157 stock options at $2.34 - Stock Titan
Wed, 06 May 2026
Biote Corp. (BTMD) Releases Q1 2026 Earnings: Revenue Falls 8.3% While EPS Beats Estimates | BTMD Stock News - Quiver Quantitative
Wed, 06 May 2026
Biote Corp (NASDAQ:BTMD) Q1 2026: Revenue Miss Despite EPS Beat - ChartMill
Wed, 06 May 2026
biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance
Mon, 04 May 2026
Biote Corp expected to post earnings of 5 cents a share - Earnings Preview - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 30 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 10.3 (%) |
| Held by Institutions | 66.6 (%) |
| Shares Short | 1,620 (K) |
| Shares Short P.Month | 1,690 (K) |
| EPS | 0.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.88 |
| Profit Margin | 8.2 % |
| Operating Margin | 9.7 % |
| Return on Assets (ttm) | 17.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -8.4 % |
| Gross Profit (p.s.) | 4.34 |
| Sales Per Share | 6.2 |
| EBITDA (p.s.) | 1.08 |
| Qtrly Earnings Growth | -83.9 % |
| Operating Cash Flow | 33 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 5.72 |
| PEG Ratio | 0 |
| Price to Book value | -1.32 |
| Price to Sales | 0.39 |
| Price to Cash Flow | 2.28 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|